Biorce, a Barcelona startup applying artificial intelligence to clinical trials, grew from about 30 to around 230 employees in twelve months. 80% of its revenue comes from the United States.
The round that the Barcelona startup Biorce closed at the beginning of 2026 amounts to $52 million, approximately 44 million euros, according to La Vanguardia. The operation, led by the US fund DST Global Partners, with participation from Norrsken VC, YZR Capital, and Mustard Seed Maze, adds to the 3.5 million euros the company had previously raised for R&D. According to Ecosistema Startup, the company has grown from about 30 people to around 230 in twelve months.
The workforce is split between 130 people at the headquarters on Diagonal Avenue and the rest in two commercial offices in the United States. In 2025, the company generated around 10 million euros, with 80% of that revenue coming from the United States. Its clients are large pharmaceutical companies, and the firm maintains around fifty clients in the sector, predominantly American, with also a presence in Europe and Asia.
The platform, called Aika, applies AI to the design and part of the development of a clinical trial, particularly to documentation, formats, cost calculations, and dates. According to Pedro Coelho, co-founder and CEO, the tool reduces the time spent on paperwork preparation and processing by 50%.
"We reduce the time spent on preparing and processing the paperwork for these complex processes by 50%," Coelho told La Vanguardia.
The company began selling in March 2024, two months after its establishment, initially with just the documentation functionalities. To cater to the US market, its top executives spent months in the offices in New York and Texas.
Coelho currently rules out a new round, although he anticipates that when it is launched, it will be "much larger". The company's priorities are product development, hiring, and expansion in Asia.

